Zydus Lifesciences Limited has informed the Exchange regarding a press release dated March 03, 2023, titled "Zydus receives final approval from the USFDA for Vigabatrin for Oral Solution USP, 500 mg".
Press Release Mar 03 2023
Filed with NSE · · 2 pages · English
Summary by 6ix AI
This medication is indicated for treating Refractory Complex Partial Seizures and infantile spasms in young patients. The drug will be manufactured at Zydus's facility in Moraiya, Ahmedabad.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Mar 02 2023
- Press Release Feb 28 2023
- Press Release Feb 24 2023
- Press Release Feb 20 2023
- Press Release Feb 17 2023
Later from Zydus Lifesciences
- Press Release Mar 07 2023
- Press Release Mar 09 2023
- Zydus Lifesciences Limited Press Release Mar 15 2023
- Press Release Mar 21 2023
- Press Release Mar 24 2023
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences